By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics and genetic analysis products developer CapitalBio has received certification from China's State Food and Drug Administration for two microarray-based tests and for one amplification-based test for tuberculosis.

The two microarray assays can identify tuberculosis from spit samples, and they were developed for use with the company's LuxScan scanning and analysis tools, according to firm, which is based in Beijing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.